ARTICLE | Clinical News
Faldaprevir: Phase IIa started
November 23, 2015 8:00 AM UTC
Trek began a double-blind, U.S. Phase IIa trial to evaluate 60 and 120 mg TD-6450 once daily with 120 mg oral faldaprevir once daily and ribavirin twice daily for 12 weeks in about 24 treatment-naive...